Scancell Holdings plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Vulpes Testudo Fund, was filed 04 Aug 2025.
Scancell Holdings plc: what insiders have been doing
Scancell Holdings plc has a thin disclosure history in our data (latest filing: 4 August 2025). New filings will appear here as soon as they are published. Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
Who traded when
BuySaleAnalyst consensus: bullish or bearish?
Analysts rate Scancell Holdings plc Strong Buy (bullish), based on 1 analysts. Average price target: £0.19.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended April 2024 · cache
- 0London Stock Exchange, AIMISIN GB00B63D3314RNS:5765862Canonical exit: 28 Oct 2025 (T+90)
- 3,000,000 shares@ £0.105100.0% of flowOutside a trading venueFCA-NSM:LSE20180201070013_13517268_20200330111413838_28026-0
- 9,000,000 shares@ £0.105100.0% of flowOutside a trading venueFCA-NSM:LSE20180201070013_13517268_20200330111413838_28026-1
- 2,500,000 shares@ £0.105100.0% of flowOutside a trading venueFCA-NSM:LSE20180201070013_13517268_20200330111413838_28026-2
- 500,000 shares@ £0.105100.0% of flowOutside a trading venueFCA-NSM:LSE20180201070013_13517268_20200330111413838_28026-3
5 of 5 declarations
About Scancell Holdings plc
Scancell Holdings plc is a UK-based biopharmaceutical company focused on developing immunotherapeutic treatments for cancer. It concentrates on innovative approaches to stimulate patients' immune systems.
